论文部分内容阅读
目的评价甘氨双唑钠(metronidazole amino acidum natrium,CMNa)对食管癌放射治疗增敏作用的疗效及安全性。方法通过计算机及手工检索,收集有关CMNa联合放疗治疗食管癌的随机对照试验(randomized con-trolled trial,RCT),按照Cochrane协作网推荐的方法进行系统评价。结果共有13项RCT、1 144例患者纳入研究,对试验数据行Meta分析。CMNa组患者在放疗基础上联合使用CMNa 800 mg/m2,3次/周,用药至疗程结束。CMNa组完全缓解率(CR=50%)显著高于单纯放疗组(CR=26%),[OR=2.80,95%CI(2.19,3.59)];有效缓解率(CR+PR=94%)也高于单纯放疗组(CR+PR=84%),[OR=2.95,95%CI(2.00,4.36)];两组不良反应发生率差异无统计学意义(P>0.05)。结论 CMNa对食管癌放射治疗的增敏效果明显,提高了食管癌放疗疗效,无明显不良反应发生,是一种安全有效的放射增敏剂。
Objective To evaluate the efficacy and safety of metronidazole amino acidum natrium (CMNa) in sensitization of radiotherapy for esophageal cancer. Methods Randomized con-trolled trials (RCTs) were conducted on CMNa combined with radiotherapy for esophageal cancer by computer and manual search. Systematic evaluation was performed according to the method recommended by Cochrane Collaboration. Results A total of 13 RCTs and 1 144 patients were included in the study and meta-analysis of the test data. In the CMNa group, CMNa 800 mg/m2 was used in combination with radiotherapy for 3 times per week, and the medication was used until the end of the treatment. The complete remission rate (CR=50%) was significantly higher in the CMNa group than in the radiotherapy alone group (CR=26%), [OR=2.80, 95%CI (2.19,3.59)]; the effective remission rate (CR+PR=94%) It was also higher than that of radiotherapy alone (CR+PR=84%), [OR=2.95, 95%CI(2.00, 4.36)]; there was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion The sensitization effect of CMNa on esophageal cancer radiotherapy is obvious, which improves the efficacy of esophageal cancer radiotherapy and has no obvious adverse reactions. It is a safe and effective radiosensitizer.